Syra Health Corp. Class A Common Stock

Q1 2025 revenue was $1.9 million, up 6% from $1.8 million a year ago. Gross profit was $589,000, up 97%, and gross margin improved to 31.7%, a 14.6 percentage-point increase year over year. Operating expenses declined 39% to $1.1 million, adjusted EBITDA was negative $462,000 versus negative $1.4 million last year, net loss improved to $472,000 from $1.4 million, and net loss per share improved to $0.04 from $0.22. Cash on hand was $2.5 million as of March 31, 2025. For full-year 2025, management withdrew prior guidance for revenue growth and profitability due to uncertainty from federal government funding changes impacting state, local, and county customers.

Deepika Vuppalanchi said the quarter reflected strong execution on a strategy focused on higher-margin, more durable revenue streams, especially Population Health and Behavioral and Mental Health. She emphasized continued investment in Syrenity, including new PTSD-focused content, and said the company is refining go-to-market efforts toward private-sector B2B customers while still pursuing public-sector opportunities. Her tone was cautiously optimistic, but she also acknowledged that federal spending changes are creating delays, cancellations, and near-term revenue and cash flow uncertainty.

Priya Prasad highlighted the financial improvement: revenue of $1.9 million, gross profit of $589,000, gross margin of 31.7%, operating expenses of $1.1 million, adjusted EBITDA of negative $462,000, net loss of $472,000, and cash of $2.5 million. She also noted the company consolidated five business units into three for reporting purposes, with Health Education and Training and Digital Health folded into Population Health. On capital allocation and outlook, she said management will keep prioritizing investments that support long-term growth while maintaining expense discipline, but withdrew full-year guidance because visibility is limited amid federal funding changes.

Investors asked about the OTC transition, and management said the company will continue quarterly reporting, timely press releases on contract wins, and transparent filings. Questions also focused on the expired Indiana FSSA NeuroDiagnostic Institute contract; management said a $1.5 million one-year extension was secured with the same customer and that the shift toward higher-margin Population Health and Behavioral and Mental Health should help offset the change. On federal contracts, management said Caduceus has no task orders yet, while LUKE bids are ongoing for MSQ2; they also confirmed federal-level funding changes are delaying RFP awards and affecting revenue timing and cash flow.